Prevention of Urinary Tract Infections. Urinary tract infection, site not specified Use additional code (B95-B98), if desired, to identify infectious agent.
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group received probiotic capsules containing 107 × 5 CFU viable lyophilized bacteria including 4 strains of Lactobacillus (Lactobacillus acidophilu
Prevention
Placebo
Intervention group: Patients in this group received probiotic capsules containing 107 × 5 CFU viable lyophilized bacteria including 4 strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus
Control group: Patients in this group took the same shape capsules without active ingredient (placebo), twice a day for seven days
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: The inclusion criteria included elder patients who aged sixty and more, and were admitted to the ICU, and did not have any limitation for taking medicine orally; Exclusion criteria: included the patients who had a history of chemotherapy previously and right now, acute bowel obstruction, short bowel syndrome and acute pancreatitis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Leukocyturia. Timepoint: Before intervention and a week after completion of taking the capsules. Method of measurement: Urinary analysis.;Urinary tract infection. Timepoint: Before intervention and a week after completion of taking the capsules. Method of measurement: urinary culture. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: On 30th day of intervention. Method of measurement: Followed up by phone call. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Niksolat
Iran University of Medical Sciences
Outcome results
None listed